Kunming Longjin Pharmaceutical Co Ltd Net Asset Quality Index
Kunming Longjin Pharmaceutical Co Ltd net asset quality index. Kunming Longjin Pharmaceutical Co Ltd (002750) has a Net Asset Quality Index of 87.4% as of March 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥555.15 Million minus total liabilities of CN¥69.96 Million yields net assets of CN¥485.19 Million. A higher index indicates a stronger, lower-leverage balance sheet. See Kunming Longjin Pharmaceutical Co Ltd book value and equity for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Kunming Longjin Pharmaceutical Co Ltd (2011–2024)
Net asset quality index of Kunming Longjin Pharmaceutical Co Ltd from 2011 to 2024. This chart shows how Kunming Longjin Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2011 to 2024. As of March 2025, the index stands at 87.4%, representing net assets of CN¥485.19 Million against total assets of CN¥555.15 Million CNY. Check Kunming Longjin Pharmaceutical Co Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Kunming Longjin Pharmaceutical Co Ltd Net Asset Quality Index by Year (2011–2024)
Kunming Longjin Pharmaceutical Co Ltd net asset quality index by year from 2011 to 2024. The table below presents the year-by-year Net Asset Quality Index for Kunming Longjin Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Kunming Longjin Pharmaceutical Co Ltd market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 86.0% | CN¥494.21 Million | CN¥574.40 Million | CN¥80.19 Million | ▲ +0.4 pp |
| 2023 | 85.7% | CN¥541.13 Million | CN¥631.63 Million | CN¥90.51 Million | ▲ +4.7 pp |
| 2022 | 80.9% | CN¥604.77 Million | CN¥747.21 Million | CN¥142.44 Million | ▼ -1.1 pp |
| 2021 | 82.0% | CN¥678.29 Million | CN¥827.28 Million | CN¥148.99 Million | ▼ -1.7 pp |
| 2020 | 83.7% | CN¥704.71 Million | CN¥841.76 Million | CN¥137.05 Million | ▲ +1.2 pp |
| 2019 | 82.5% | CN¥665.89 Million | CN¥806.89 Million | CN¥141.00 Million | ▼ -0.8 pp |
| 2018 | 83.3% | CN¥655.93 Million | CN¥787.55 Million | CN¥131.62 Million | ▲ +1.1 pp |
| 2017 | 82.2% | CN¥645.54 Million | CN¥785.23 Million | CN¥139.69 Million | ▼ -6.0 pp |
| 2016 | 88.3% | CN¥670.46 Million | CN¥759.68 Million | CN¥89.22 Million | ▲ +2.5 pp |
| 2015 | 85.8% | CN¥599.41 Million | CN¥698.86 Million | CN¥99.45 Million | ▲ +20.2 pp |
| 2014 | 65.6% | CN¥285.57 Million | CN¥435.59 Million | CN¥150.02 Million | ▼ -2.7 pp |
| 2013 | 68.2% | CN¥302.00 Million | CN¥442.56 Million | CN¥140.57 Million | ▲ +6.6 pp |
| 2012 | 61.7% | CN¥226.94 Million | CN¥368.05 Million | CN¥141.11 Million | ▼ -3.3 pp |
| 2011 | 65.0% | CN¥186.74 Million | CN¥287.36 Million | CN¥100.62 Million | — |